fbpx

Bristol Myers Squibb Resolves False Claims Act Allegations

Last month, Bristol Myers Squibb (BMS) reached an agreement with the United States and participating states to pay 75 million dollars plus interest in order to resolve False Claims Act allegations. The government contends that BMS underpaid the rebates owed under the Medicaid Drug Rebate Program (MDRP). Of the 75 million dollar payout, 41 million dollars will be paid to the United States and 34 million dollars will be paid to states involved in the settlement. 

The MDRP makes it mandatory for drug manufacturers to pay quarterly rebates to state Medicaid programs in exchange for Medicaid coverage of their medications. The rebates are determined using the Average Manufacturer Prices (AMPs), which are reported to the government by the manufacturers. In general, the higher the AMP, the greater the rebate paid by the manufacturer to the Medicaid programs. 

Between 2007 and 2013, BMS underreported the AMPs for various drugs by reducing the AMPs for service fees paid to wholesalers. Additionally, from 2014 to 2016, the company excluded additional value received based on price appreciation in contracts with wholesalers, also lowering the AMP. Thus, BMS underpaid quarterly rebates owed to participating states for nearly a decade, causing the United States to be overcharged for its payments to each state’s Medicaid program. 

The case was presented under the whistleblower provisions of the False Claims Act. The whistleblower, a former head of healthcare industry trade group, first filed the lawsuit in 2013, but the government declined to intervene. Dan Miller of Walden Macht & Maran represented the whistleblower and believes the results speak for themselves: “We took this case to the brink of trial and prevailed.”

BMS, however, did not admit any guilt despite the settlement. A company spokesperson said, “Bristol Myers Squibb acted responsibly and in good faith in interpreting these regulations, and we deny that any wrongdoing occurred in this matter.” 


For more information about this case, contact us today.

Tracy Everhart is the Editor for Drug Law Journal. A highly-trained and certified medical professional, Tracy is also an accomplished medical writer. After spending years on the front lines of the medical profession, Tracy now devotes her expertise and skills to researching and reporting on new drugs and devices that enter the market, as well as their side-effects and the real-life stories involved. Prior to joining Drug Law Journal, Tracy wrote for benchmark online healthcare resources focused on families and, in particular, women’s health issues. Tracy holds post-graduate degrees from both the American College of Healthcare Sciences and the Yale School of Nursing. She is also a graduate of both Hampshire College, where she studied microbiology and the University of South Carolina school of nursing.

Drug Law Journal Legal Sponsorship

Drug Law Journal's publishing and research are sponsored by the DDP Injury Law Group in Washington, D.C. Their legal team is focused on protecting the rights of injury victims.
Furthermore, they understand and appreciate the importance of a trusted attorney-client relationship.
The DDP Injury Law Group uses their years of experience with litigation to ensure their clients can fight for the compensation they deserve.

Always seek the advice of a medical professional when making personal health choices.

The Offices of DrugLawJournal.com are located at:

1800 North Orange Avenue, Suite C
Orlando, Florida 32804

DrugLawJournal.com is sponsored by the DDP Injury Law Group, and therefore may be considered attorney advertising. The information contained on DrugLawJournal.com is provided for informational purposes only, and should not be construed as legal or medical advice on any subject matter. No viewers of this site should discontinue taking a prescribed medication on the basis of any information on this site and should always first consult with a doctor concerning any medication. Viewers should understand that if they refrain from taking prescribed medication without appropriate medical advice they can suffer injury or death.

No viewers of content from this site, clients or otherwise, should act or refrain from acting on the basis of any content included in the site without seeking the appropriate legal or other professional advice on the particular facts and circumstances at issue from an attorney licensed in the viewer’s state. Viewing information from DrugLawJournal.com does not create an attorney-client relationship between you and DDP Injury Law Group or DrugLawJournal.com nor is it intended to do so.The content of DrugLawJournal.com may not reflect current legal developments, verdicts or settlements. Prior results do not predict a similar outcome. For more information, please visit our web site’s disclaimer.

©2024 DrugLawJournal.com | Privacy Policy | Terms & Conditions

Stay Informed

Sign up to receive peroidic updates from our expert team of researchers, highlighting defective drugs, devices, and legal issues related to your health.

Email Catcher
Free Drug and Medical Device Case Review

Free Drug and Medical Device Case Review

Share your story with us and we will reach out to you about your case.

First
Last
Described what happened to you, we will review and reach out to you about your situation.

It is important for those who have suffered injury from dangerous drugs and medical devices to know that they have may have options.

Consumers have the ability to seek legal remedies for their injuries resulting from the negligence of drug and device manufacturers. The first step toward justice and recovery is sharing your story with effective legal counsel. An attorney will help you to better understand the issues and discuss the possibility of compensation for your suffering.

Once you complete the information request above, Drug Law Journal will send the information to a specialist at our legal sponsor’s firm, the DDP Injury Law Group, in Washington, D.C. That specialist will follow-up with you directly to gather further specific information about your case and make an evaluation. If the firm is able to move forward on your case, they will also discuss next steps. Remember – the entire consult and evaluation is free to you. You only need to take the first step to fill out the contact form or call: (800) 597-1870 for immediate assistance.